US · guidance

NCD 20.22

Ethylenediamine-Tetra-Acetic (EDTA) Chelation Therapy for Treatment of Atherosclerosis

activein force · 1966-01-01 – presentact-effective-date

Indications and Limitations of Coverage

The use of EDTA as a chelating agent to treat atherosclerosis, arteriosclerosis, calcinosis, or similar generalized condition not listed by the FDA as an approved use is not covered. Any such use of EDTA is considered experimental.

Cross Reference

See §20.21 of the NCD Manual.

History

Version 1

Provenance

Source: cms.gov
Retrieved: 2026-08-26
Edition: mcd-2026-08-26
Content hash: 85e75fd7a12f8db3fa4eaa5d54353ff3ae93ded12371cfb3b958373ccf934702

View the official source →

The link goes to the issuing authority’s own document — the one we read to produce this record. Where a source publishes whole titles rather than sections, your browser may need a moment to jump to the provision.

Unofficial copy of government-published law, reproduced from official sources with full provenance. Not an official publication; verify against official sources before relying on it in a filing. Records in the 'guidance' corpus, and only that corpus, are sub-regulatory (interpretive guidelines, survey procedures) and are not binding law. Validity bounds follow each jurisdiction's declared temporalBasis.

Coverage · API docs